NCT02047019 - Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil | Biotech Hunter

Timeline

Start Date

December 1, 2017

Primary Completion Date

December 8, 2019

Study Completion Date

December 8, 2019

Conditions

Hypertension

Interventions

DRUG

Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)

Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 30/16 mg, tablet, orally, once daily

DRUG

Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)

Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16 mg, tablet, orally, once daily

DRUG

Candesartan Cilexetil

Candesartan Cilexetil, 16 mg, capsule, orally, once daily

DRUG

Candesartan matching placebo

Candesartan matching placebo, capsule, orally, once daily

DRUG

Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo

Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo, tablet, orally, once daily

DRUG

Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)

Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16mg matching placebo, tablet, orally, once daily

Trial Locations (8)

Fondazione Salvatore Maugeri, Pavia

AULSS 07 Pieve Soligo, Treviso

AAS 3 Friuli Alto Medio Collin, Udine

A.O.U. di Bologna Policlinico S.Orsola Malpighi, Bologna

A.O.U. Pisana, Pisa

Fondazione Università G.D'Annunzio, Chieti

IRCCS Ist Neurologico Mediterraneo, Isernia

A.O.U. di Sassari, Sassari